Further exploration of targeted inhibition of CD39-CD73-eAdo/A2aR alone or combined with other immunotherapy, radiotherapy, and chemotherapy in treating various cancer types and developing effective clinical therapeutic drugs are continuous research hotspots in this field. The gene discussed is NT5E; the disease is cancer.